MedTrace Logo

Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)

NCT02361424 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2016-02-15

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy on cognitive impairment and functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen at low dose) in patients with mild Alzheimer Disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

PXT00864

PXT00864 is a fixed-dose combination of baclofen and acamprosate

DRUG

placebo

Sponsors & Collaborators

  • Ascopharm Groupe Novasco

    collaborator OTHER

  • Pharnext S.C.A.

    lead OTHER

Principal Investigators

  • Jean-Marc Orgogozo, MD · Hospital Pellegrin, Bordeaux, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02361424 on ClinicalTrials.gov